Gefitinib as the first-line treatment in metastatic adenocarcinoma patients with EGFR mutation-positive: A single-centre retrospective cohort study in Hospital Pulau Pinang, Malaysia

被引：0
|
作者：
Appava, Sumithra [1 ]
Subramaniam, Deepa Priya Naidu [1 ]
Muneswarao, Jaya [2 ]
Tan, Ai Lian [3 ]
Pereirasamy, Lalitha [1 ]
Goon, Ai Khiang [1 ]
Muthukumaru, Umadevi [1 ]
Ali, Irfhan Ali Hyder [1 ]
机构：
[1] Hosp Pulau Pinang, Resp Dept, George Town, Malaysia
[2] Hosp Pulau Pinang, Dept Pharm, George Town, Malaysia
[3] Hosp Pulau Pinang, Dept Oncol, George Town, Malaysia
来源：
RESPIROLOGY | 2023年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
AP08-338
引用
收藏
页码：318 / 319
页数：2
相关论文
共 50 条
  • [31] Audit of gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in patients with EGFR mutation
    Douglas, R.
    Campbell, L.
    McAleese, J.
    Scullin, P.
    LUNG CANCER, 2013, 79 : S9 - S9
  • [32] First-Line Gefitinib for EGFR-Mutated Lung Adenocarcinoma Patients with Bone Metastases - A Single Institution Experience
    Radosavljevic, Davorin
    Spasic, Jelena
    Stanic, Nemanja
    Ristic, Marija
    Ratknic, Milos
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1233 - S1233
  • [33] First-Line Afatinib vs Gefitinib for Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: The LUX-Lung 7 Trial
    Aix, Santiago Ponce
    Park, Keunchil
    Tan, Eng-Huat
    O'Byrne, Kenneth
    Zhang, Li
    Boyer, Michael
    Mok, Tony
    Hirsh, Vera
    Yang, James Chih-Hsin
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S203 - S204
  • [34] Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
    Schuler, A.
    Huser, J.
    Schaer, S.
    Schmid, S.
    Scherz, A.
    Gautschi, O.
    Mauti, L. A.
    Von Briel, T.
    Waibel, C.
    De Nicola, L. Wannesson
    Pankovics, J.
    Mark, M. T.
    Rothschild, S. I.
    Addeo, A.
    Janthur, W-D.
    Siano, M.
    Britschgi, C.
    Frueh, M.
    ANNALS OF ONCOLOGY, 2022, 33 : S1584 - S1585
  • [35] A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients
    Scagliotti, Giorgio
    Moro-Sibilot, Denis
    Kollmeier, Jens
    Favaretto, Adolfo
    Cho, Eun Kyung
    Grosch, Heidrun
    Kimmich, Martin
    Girard, Nicolas
    Tsai, Chun-Ming
    Hsia, Te-Chun
    Brighenti, Matteo
    Schumann, Christian
    Wang, Xuejing Aimee
    Wijayawardana, Sameera R.
    Gruver, Aaron M.
    Wallin, Johan
    Mansouri, Kambiz
    Wacheck, Volker
    Chang, Gee-Chen
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (01) : 80 - 90
  • [36] NICE guidance on erlotinib for first-line treatment of EGFR-TK mutation-positive advanced or metastatic non-small-cell lung cancer
    Dillon, Bernice
    Naidoo, Bhash
    Knight, Helen
    Clark, Peter
    LANCET ONCOLOGY, 2012, 13 (08): : 764 - 765
  • [37] Outcome of Uncommon EGFR Mutation Positive Newly Diagnosed Advanced NSCLC Patients: A Single-Centre Retrospective Analysis
    Kate, S.
    Choughule, A.
    Joshi, A.
    Noronha, V.
    Pati, V.
    Dusane, R.
    Tiwrekar, P.
    Solanki, L.
    Trivedi, V.
    Prabhash, K.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S477 - S477
  • [38] Efficacy and safety of first-line gefitinib treatment in metastatic lung adenocarcinoma patients with sensitizing EGFR mutation determined by ddPCR in plasma cell-free DNA (BENEFIT trial)
    Wang, J.
    Cheng, Y.
    Wu, Y-L.
    An, T.
    Gao, H.
    Wang, K.
    Zhou, Q.
    Hu, Y.
    Song, Y.
    Ding, C.
    Ye, X.
    Peng, F.
    Liang, L.
    Hu, Y.
    Huang, C.
    Zhou, C.
    Shi, Y-K.
    Zhang, L.
    Gu, Y.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] Randomized, Double-Blind Study of Erlotinib Plus Ramucirumab or Placebo in First Line for Patients with EGFR Mutation-Positive Metastatic NSCLC
    Polit, R. R.
    Reck, M.
    Juan Vidal, O.
    Nadal, E.
    Lee, P.
    Alexandris, E.
    He, S.
    Nakagawa, K.
    Garon, E. B.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1577 - S1577
  • [40] Cost Effectiveness of Dabrafenib as a First-Line Treatment in Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma in Canada
    Thomas E. Delea
    Jordan Amdahl
    Alice Wang
    Mayur M. Amonkar
    Marroon Thabane
    PharmacoEconomics, 2015, 33 : 367 - 380
12345